首页> 外文期刊>British Journal of Clinical Pharmacology >Inhibition of CYP2D6-mediated tramadol O-demethylation in methadone but not buprenorphine maintenance patients
【24h】

Inhibition of CYP2D6-mediated tramadol O-demethylation in methadone but not buprenorphine maintenance patients

机译:抑制CYP2D6介导的曲马多O-去甲基化对美沙酮但对丁丙诺啡维持患者的抑制作用

获取原文
获取原文并翻译 | 示例
           

摘要

AIMS To compare the O- (CYP2D6 mediated) and N- (CYP3A4 mediated) demethylation metabolism of tramadol between methadone and buprenorphine maintained CYP2D6 extensive metabolizer subjects. METHODS Nine methadone and seven buprenorphine maintained subjects received a single 100mg dose of tramadol hydrochloride. Blood was collected at 4h and assayed for tramadol, methadone, buprenorphine and norbuprenorphine (where appropriate) and all urine over 4h was assayed for tramadol and its M1 and M2 metabolites. RESULTS The urinary metabolic ratio [median (range)] for O-demethylation (M1) was significantly lower (P= 0.0002, probability score 1.0) in the subjects taking methadone [0.071 (0.012-0.103)] compared with those taking buprenorphine [0.192 (0.108-0.392)], but there was no significant difference (P= 0.21, probability score 0.69) in N-demethylation (M2). The percentage of dose [median (range)] recovered as M1 was significantly lower in subjects taking methadone compared with buprenorphine (0.069 (0.044-0.093) and 0.126 (0.069-0.187), respectively, P= 0.04, probability score 0.19), M2 was significantly higher in subjects taking methadone compared with buprenorphine (0.048 (0.033-0.085) and 0.033 (0.014-0.049), respectively, P= 0.04, probability score 0.81). Tramadol was similar (0.901 (0.635-1.30) and 0.685 (0.347-1.04), respectively, P= 0.35, probability score 0.65). CONCLUSIONS Methadone inhibited the CYP2D6-mediated metabolism of tramadol to M1. Hence, as the degree of opioid analgesia is largely dependent on M1 formation, methadone maintenance patients may not receive adequate analgesia from oral tramadol.
机译:目的比较美沙酮与丁丙诺啡维持的CYP2D6广泛代谢者之间曲马多的O-(经CYP2D6介导)和N-(CYP3A4介导)脱甲基代谢。方法9名美沙酮和7名维持丁丙诺啡的受试者接受单次100mg盐酸曲马多的剂量。在第4小时收集血液,并测定曲马多,美沙酮,丁丙诺啡和去甲丁啡(适当时),并在4小时以上的所有尿液中测定曲马多及其M1和M2代谢产物。结果与服用丁丙诺啡[0.192]的受试者相比,服用美沙酮[0.071(0.012-0.103)]的受试者中O-去甲基化(M1)的尿代谢率[中位数(范围)]显着降低(P = 0.0002,概率得分1.0)。 (0.108-0.392)],但N-去甲基化(M2)没有显着差异(P = 0.21,概率得分0.69)。与丁丙诺啡相比,服用美沙酮的受试者通过M1恢复的剂量[中位数(范围)]的百分比显着较低(分别为0.069(0.044-0.093)和0.126(0.069-0.187),P = 0.04,概率得分0.19),M2与丁丙诺啡相比,服用美沙酮的受试者明显更高(分别为0.048(0.033-0.085)和0.033(0.014-0.049),P = 0.04,概率得分0.81)。曲马多相似(分别为0.901(0.635-1.30)和0.685(0.347-1.04),P = 0.35,概率得分0.65)。结论美沙酮能抑制CYP2D6介导的曲马多向M1的代谢。因此,由于阿片类药物的镇痛程度主要取决于M1的形成,因此美沙酮维持治疗患者可能无法从口服曲马多接受足够的镇痛作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号